Current directions of incretinotropic therapy in children - balance of efficiency and safety

Gastrointestinal peptides, incretins, and their influence on the development of metabolic disorders, as well as new approaches to incretinotropic therapy, are currently being actively studied.Gastrointestinal peptides are considered as potential drugs that can play an essential role in the treatment of various human diseases. Numerous studies confirm the important properties of these peptides and their impact on obesity, non-alcoholic fatty liver disease, type 2 diabetes, and other metabolic disorders. Liraglutide, an analogue of human glucagon-like peptide-1 (GLP-1), which is a physiological regulator of appetite and food intake, is approved for use in pediatrics. By mimicking the action of GLP-1, liraglutide slows down the digestion of food, regulates its movement in the gastrointestinal tract, has a positive effect on the functioning of pancreatic cells, reduces blood glucose levels, and helps reduce the amount of fat and decrease body weight.